Abstract
Introduction
The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regimen. Further real-world evidence is needed to support the effectiveness of 8-week G/P in a clinical practice setting and to consolidate these treatment recommendations. The aim of this study is to contribute real-world evidence for the effectiveness of an 8-week G/P treatment in TN/CC patients with HCV genotypes 1–6.
Methods
Retrospective real-world data from 494 TN/CC patients with HCV genotypes 1–6 were collected between August 2017 to December 2020 from the Symphony Health Solutions administrative claims database. Demographic and clinical characteristics were collected at baseline. Patients were required to have a follow-up HCV ribonucleic acid level at least 8 weeks or more after the end of treatment. The percentage of patients achieving a sustained virologic response (SVR) is reported.
Results
The majority of patients were male (58%) and Caucasian (40%), with a mean age of 58 years; 74%, 12%, 12%, and 1% of patients were HCV genotype 1, 2, 3, and 4–6 infected, respectively. SVR was achieved in 95.5% of all patients. Across patient subgroups, SVR was achieved in 95.6% of patients with HCV genotype 3 and in 93% of HCV patients with a recent diagnosis of illicit drug use or abuse (within 6 months prior to G/P initiation).
Conclusion
Early real-world evidence indicates high effectiveness of the 8-week G/P regimen in TN/CC patients of HCV genotypes 1–6 from a large US claims database.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regimen, including HCV genotype 3 and patients with a recent diagnosis of illicit drug use or abuse |
This study presents real-world evidence for the effectiveness of 8-week G/P in TN/CC patients with HCV |
What was learned from the study? |
Overall, 8-week G/P treatment in TN/CC HCV patients was highly effective, with an overall cure rate of 95.5%, including in patients with genotype 3 (95.6%) and patients with a recent diagnosis of illicit drug use or abuse (93%) |
Results from this real-world analysis provide further evidence for the 8-week G/P regimen as an efficacious and short-duration treatment in TN/CC patients with all HCV genotypes in this real-world setting |
This study redefines the historical length of treatment for TN/CC HCV patients, supporting efforts towards the World Health Organization’s goal of eliminating HCV as a major public health threat by 2030 |
Introduction
Globally, an estimated 71 million people have chronic hepatitis C virus (HCV) infection [1]. In the United States (US), it was estimated that 2.4 million people had active HCV between 2013 and 2016 [2]. In 2018, an estimated 50,300 new acute and 137,713 new chronic cases of HCV were identified in a noninstitutionalized civilian population in the US [3]. Chronic HCV is associated with progressive liver disease [4], extrahepatic manifestations [5], and an increase in all-cause mortality [6]. The introduction of oral, pangenotypic, ribavirin-free, direct-acting antiviral (DAAs) drugs has improved the efficacy and safety of HCV treatment. DAAs are generally well tolerated and are associated with high cure rates [7]. Specifically, glecaprevir/pibrentasvir (G/P) has been approved for the treatment of patients with chronic HCV without cirrhosis or with compensated cirrhosis (CC) [8, 9], where up to 98% of patients can achieve a sustained virologic response at post-treatment week 12 (SVR12) by G/P treatment in only 8 weeks [10]. By curing HCV infection, health-related quality of life can be improved, and extrahepatic manifestations [11] and onward transmission can be prevented [8].
Previously, only treatment-naïve (TN) patients without cirrhosis and with HCV genotypes 1–6 were eligible for an 8-week regimen of G/P [12]. The results of the EXPEDITION-8 trial [10] demonstrated the efficacy and safety of 8-week G/P in TN patients with HCV genotypes 1–6 and CC, including those with genotype 3, leading to approval and label updates for an 8-week treatment duration in these patients in September 2019 in the US [13, 14] and March 2020 in the EU [15, 16]. HCV genotype 3 is more difficult to treat and has been associated with significantly lower SVR rates than other genotypes [17]. Prior to the EXPEDITION-8 trial outcomes, a highly effective 12-week regimen of G/P for TN/CC patients with genotype 3 yielded high rates of SVR [18, 19]. Both the American Association of the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) guidelines previously recommended a 12-week regimen of G/P for TN/CC patients with genotype 3; currently, AASLD recommends 8 weeks of G/P treatment for TN/CC patients with genotype 3, and EASL recommends 8 to 12 weeks of treatment for these patients [8, 9]. Therefore, the new guidelines and label update for a shorter-duration treatment are especially promising for patients infected with more difficult-to-treat HCV infections, such as genotype 3, and for populations that are more difficult to engage and retain in therapy, such as people who inject drugs (PWID) [20, 21].
Evidence from clinical trials demonstrates that TN/CC patients with genotypes 1–6 who received treatment for G/P for 8 weeks achieved high rates of SVR12 [10, 22, 23]. However, the most-recently published EASL guidelines state that real-world data are needed to consolidate the shortened treatment recommendation of an 8-week regimen [8]. Real-world effectiveness data are promising [24, 25], but data from the US are limited. The first real-world evidence from the US demonstrated a high SVR12 rate (≥ 95%) following an 8-week regimen of G/P for TN/CC patients with genotype 1–6 chronic HCV infection [26]. The aim of this study is to assess the real-world effectiveness of 8-week G/P in TN/CC patients with chronic HCV infection using information from a large US claims database.
Methods
Study Design and Data Source
This was a retrospective, real-world study that examined SVR12 rates among TN/CC patients with HCV in the US who were treated with 8-week G/P. Real-world, anonymized data from across the US between August 2017 and December 2020 were collated from the Symphony Health Solutions (SHS) administrative claims database, a large and geographically diverse set of commercial and government (Medicare and Medicaid) electronic claims processors. Anonymized data were linked to patient-level laboratory results from laboratory testing companies in the US.
Patients
Patients were included in the study if they were over the age of 12, had a diagnosis of chronic HCV within 6 months prior to the initial G/P prescription dispensed, and received a diagnosis of cirrhosis (see Fig. 1). Patients were treated with 8-week G/P, defined as a G/P prescription filled for a total days-of-supply of 56 days, with no more than a 7-day gap between fills allowed. A previous publication found that patients with a gap of less than 7 days between fills of G/P can still achieve SVR [27].
For all patients, G/P was prescribed to be taken orally, once daily, at a fixed dose of 300 mg/120 mg, for 8 weeks [15]. Given that SHS is an open-system claims database, patients were required to have medical or pharmacy claims recorded in the 6 months before the first G/P fill date (as a pre-index proxy for 6 months enrollment), where the index date is defined as the date for the first fill of 8-week G/P. Additionally, patients were required to have a claim recorded any time post the 6-month baseline period as a proxy for continuous enrollment.
Patients were excluded if they received HCV treatment any time before their G/P initiation, had decompensated cirrhosis (excluding those with a prior history of codes associated with hepatic decompensation or hepatic failure any time before their index date; see Table S1 in the Supplementary Information), or had a liver or kidney transplant (excluding those with a prior history of codes for liver or kidney failure any time before their index date; see Table S2 in the Supplementary Information). Patients were required to have a follow-up HCV ribonucleic acid (RNA) level at least 8 weeks or more after the end of treatment. Inconclusive results were excluded.
Data Collection
Demographic and clinical characteristics were collected at baseline, including age, gender, payer type, ethnicity, geographic location, and comorbidities (liver-related diseases, HBV infection, extrahepatic manifestations [see Table S3 in the Supplementary Information], illicit drug use [see Table S4 in the Supplementary Information], and portal hypertension). Laboratory values were also collected at baseline, and included HCV genotype, alanine aminotransferase, HCV RNA viral load, platelet, serum albumin, total bilirubin, and ICD-10 for cirrhosis.
Outcome
The primary outcome in this study is the SVR rate, calculated in patients who have an HCV RNA level observed at least 8 weeks after the end of G/P treatment. Where the HCV RNA value is undetectable or unquantifiable, it means that SVR was achieved, while a quantifiable HCV RNA means that SVR was not achieved.
Statistical Analysis
Descriptive statistics were performed to assess patient characteristics at baseline. The number and percentage of eligible patients with each baseline clinical characteristic and the number and percentage of patients with a diagnosis of a disease among the comorbidities was calculated. The percentage of patients who achieved SVR was calculated among all patients who had an HCV RNA value at least 8 weeks after the end of treatment. Subgroup analyses were explored to repeat the SVR rates based on individual patient’s baseline viral load, HCV genotype, and comorbidities. Univariate comparisons of patient characteristics between patients who achieved SVR and patients who failed to achieve SVR were made using t-tests for continuous variables and chi-square tests for categorical variables. All statistical tests were two-sided and P < 0.05 was considered to be statistically significant. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc.).
Ethics
Data provided for the study were de-identified and Health Insurance Portability and Accountability Act (HIPAA) compliant; therefore, review board approval was not required.
Results
Patient Attrition
The overall sample size was 123,942 patients treated with G/P (see Fig. 1). Of these, 4139 patients were HCV treatment-naïve, had compensated cirrhosis, and did not receive a liver or kidney transplant. Of these, 494 patients met the inclusion and exclusion criteria and had a follow-up HCV RNA level assessed at least 8 weeks or more after the end of treatment, of whom 45 patients were identified as genotype 3.
Patient Characteristics
The majority (58%) of the 494 HCV patients included in this analysis were male, Caucasian (40%), and had a mean age of 58 years (see Table 1). Overall, 74%, 12%, 12%, and 1% of the patients were genotype 1, 2, 3, and 4–6 infected, respectively. Of the 494 patients, 24% had a recent diagnosis of illicit drug use or abuse and 39% had one or more extrahepatic manifestations, which are the diseases defined in Table S3 in the Supplementary Information. The mean HCV RNA viral load for the total population at baseline was 4,634,921 IU/mL, and the mean platelet count was 218.6 × 109/L (see Table 2).
SVR Rates
SVR was achieved in 95.5% (n = 472) of all TN/CC HCV patients (see Fig. 2). Across patient subgroups, SVR was achieved in 95.6% (n = 43) of patients with HCV genotype 3, 95.7% (n = 155) of patients with a recent physician visit with a diagnosis of cirrhosis, 100% (n = 14) of patients with genotype 3 and a recent diagnosis of cirrhosis, 97% (n = 32) of patients with HCV genotype 3 and a recent chronic HCV diagnosis, 96.9% (n = 219) of patients showing signs of portal hypertension, and 93% (n = 107) of patients with a recent diagnosis of illicit drug use or abuse. “Recent” was defined as within 6 months prior to G/P initiation.
There was no statistically significant difference in demographics when comparing patients who achieved SVR with those who did not, including age, gender, and race/ethnicity. Of those who achieved SVR, 23% were recent illicit drug users and 38% had an extrahepatic manifestation, whereas among those who did not achieve SVR (defined as a detectable HCV RNA level), 36% had a diagnosis of illicit drug use or abuse within 6 months prior to their G/P treatment and 50% had an extrahepatic manifestation (see Table 2).
There was no statistically significant difference in patients’ baseline laboratory values, including ALT, bilirubin, serum albumin, and RNA viral load (see Table 2). This is likely due to the small sample size of patients who failed to achieve SVR.
Among the 4139 patients identified as not having had a kidney or liver transplant and who had an HCV RNA test earlier than 8 weeks post-treatment, 275 had an HCV RNA test post-treatment in weeks 0–4, of whom 97.5% (268/275) had undetectable HCV RNA. Of the 129 patients who had an HCV RNA test post-treatment in weeks 4–8, 98.5% (127/129) had undetectable HCV RNA.
Discussion
This real-world study demonstrates the high effectiveness (95.5%) of 8-week G/P in TN/CC patients with HCV genotypes 1–6. These results provide further evidence of real-world data on the 8-week effectiveness of G/P in TN/CC HCV patients. This is the first study to use a large claims-linked laboratory dataset to evaluate the SVR in HCV patients with CC treated with 8-week G/P.
The results of this study are consistent with outcomes of clinical trials [10, 22, 23] and early real-world evidence [26]. In the EXPEDITION-8 trial, 99.7% of TN/CC patients with genotypes 1–6 achieved SVR12 in the per protocol (PP) population, and 97.7% of the corresponding patients in the intention-to-treat (ITT) population achieved SVR12 [10]. When compared to baseline clinical characteristics of the EXPEDITION-8 trial, the median platelet count of patients in this study was higher (212 × 109/L versus 151 × 109/L), though the HCV RNA median viral load (6.3 log10 IU/mL [2,120,000 IU/mL] versus 6.3 log10 IU/mL), the albumin level, and the percentage of patients considered recent illicit drug users were all similar. In the current research and in the EXPEDITION-8 trial, achievement of SVR did not depend on the patient or viral characteristics present before treatment [10]. Minor differences in SVR rates between studies may be attributed to a more heterogenous real-world population, especially since clinical trials have stricter criteria for enrollment compared with real-world studies, as well as potential differences in adherence.
In the current study, the high rate of SVR achieved was observed across patient subgroups, consistent with other G/P real-world research [28]. SVR rates in patients with genotype 3 are of particular interest due to the difficulty in achieving SVR with other therapies [29, 30]. Of the genotype 3 patients in our study, 95.6% achieved SVR. These results replicate outcomes from the EXPEDITION-8 trial in which the SVR12 rate was 98.4% in the PP population and 95.2% in the ITT population for patients with genotype 3 [10]. In data pooled from phase 2 and 3 trials, 97% of ITT and 100% of modified ITT of genotype 3 TN patients with cirrhosis achieved SVR12 after 12 weeks of G/P [19]. In recent real-world research, there were only 4 TN/CC patients with genotype 3, all of whom achieved SVR12 on 8-week G/P [26]; the efficacy and smaller number of patients with genotype 3 are consistent with the current study. Therefore, 8-week G/P provides an efficacious and shorter-duration treatment for patients diagnosed with the more challenging-to-treat genotype 3.
PWID patients account for a growing number of new cases and are a target population for elimination of the disease [9]. Of patients with a recent diagnosis of illicit drug use or abuse, 93% achieved SVR in this study. By comparison, in phase 2 and 3 trials for G/P, 89% of current/recent PWID patients and 98% of former/non-PWID patients achieved SVR [13]. In those trials, recent/current PWID participants were more likely to be TN (94%) and had higher proportions of HCV genotype 3 infection (44%) and HIV co-infection (24%) when compared to former/non-PWID participants. PWID patients face many barriers to accessing and engaging in healthcare [21, 31], and follow-up appointments after treatment can be a challenge to attend [32]. Therefore, PWID HCV patients may benefit from a shorter HCV treatment duration.
In the current study, 97.5% of patients had undetectable HCV RNA as early as 0–4 weeks after the end of treatment. A recent clinical trial found that achieving SVR4 following 8 weeks of G/P was highly predictive of long-term SVR [33]. This validates the reliability of a shorter-term follow-up and can provide a shorter-duration yet effective therapy for treating and curing patients of HCV, particularly those who face barriers to accessing healthcare. In support of a shorter follow-up period, recent EASL guidelines recommend that SVR testing can be omitted for patients who are adherent and who are not high risk [8].
This study provides real-world evidence for the recommendations outlined in the AASLD and EASL guidelines of 8-week G/P treatment in TN/CC patients [8, 9], especially for those infected with HCV genotype 3 or who have advanced liver diseases. The added benefits of an 8-week therapy for patients with HCV, regardless of genotype and CC status, include simplified treatment and reduced costs [34].
There are limitations on the generalizability of these findings, as this study was conducted using patients in the Symphony Health Analytic Dataset. The population described (n = 494) represent < 1% of both the total population of patients’ data retrieved from SHS and those that met the criteria for this study. While there were only three patients under genotype 4–6, this is consistent with US population estimates [35, 36]. The results for effectiveness represent patients with available HCV RNA data post-treatment, essentially eliminating patients lost to follow-up. In addition to this, patients were required to have a follow-up HCV RNA level at least 8 weeks after the end of treatment, and so no minimum end-of-treatment follow-up was required. Therefore, the post-treatment follow-up time was not assessed. It was confirmed that the prescription for 8-week G/P was dispensed, but we cannot be certain that patients followed the prescription directions which may impact SVR rates. Due the high effectiveness rate of 8-week G/P, there were a limited number of patients available to assess patient characteristics that did not achieve SVR.
Conclusion
In summary, it is evident that the 8-week G/P regimen provides an efficacious and short-duration treatment in TN/CC patients of all HCV genotypes in this real-world setting. Clinical trial results, combined with the growing body of real-world evidence, can instill physicians with confidence when prescribing 8 weeks of G/P for TN/CC HCV patients. This study redefines the historical length of treatment for TN/CC HCV patients, supporting efforts to eliminate HCV as a major public health threat by 2030.
References
WHO. Hepatitis C fact sheet https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Hepatitis%20C%20is%20a%20liver,major%20cause%20of%20liver%20cancer2020 [
Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology. 2019;69(3):1020–31.
Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases—United States, 2009–2018. Morb Mortal Wkly Rep. 2020;69(14):399.
Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol. 2015;7(14):1843.
Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172.
Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, et al. All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016;62(3):289–97.
Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy. Side effects and complications. Visc Med. 2019;35(3):161–70.
European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–218.
IDSA-AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Arlington/Alexandria: Infectious Disease Society of America/American Association for the Study of Liver Diseases; 2020.
Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2020;72(3):441–9.
Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017;1(5):439–52.
Flamm SL, Kort J, Marx S, Strezewski J, Bacon B, Curry MP, et al. Effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO health network. Anxiety. 2018;98(560):18.
AbbVie Ltd. Mavyret (full prescribing information). 2020. https://www.rxabbvie.com/pdf/mavyret_pi.pdf. Accessed on 6 April 2021.
AbbVie Ltd. AbbVie receives FDA approval of Mavyret® (glecaprevir/pibrentasvir) to shorten treatment duration to eight weeks for treatment-naïve patients with chronic hepatitis C and compensated cirrhosis across all genotypes. 2019. https://news.Abbvie.Com/news/press-releases/abbvie-receives-fda-approval-mavyret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-nave-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes.Htm. Accessed on 28 June 2021.
AbbVie Ltd. Maviret: product information. 2017. https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_en.pdf. Accessed on 17 March 2021.
AbbVie Ltd. European Commission grants AbbVie marketing authorization shortening Maviret® (glecaprevir/pibrentasvir) treatment duration to eight weeks for treatment-naïve chronic HCV patients with genotype 3 and compensated cirrhosis. 2020. https://news.Abbvie.Com/news/press-releases/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.Htm. Accessed on 28 June 2021.
D’Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379–87.
Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018;67(2):514–23.
Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, et al. Glecaprevir/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2019;26(3):337–49.
Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, et al. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend. 2019;194:487–94.
Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. ‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246–54.
Jacobson IM, Welzel T, Dylla D, Luetkemeyer A, Feld JJ, Moreno C, et al., editors. Impact of prescribed treatment duration on hepatitis C treatment adherence: comparison of 8- and 12-week treatment with glecaprevir/pibrentasvir. In: Hepatology. Hoboken: Wiley; 2019.
Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, et al. Eight weeks of treatment with glecaprevir/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2544–53 e6.
Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, et al. Real-world clinical practice use of 8-week glecaprevir/pibrentasvir in treatment-naive patients with compensated cirrhosis. Adv Ther. 2020;37(9):4033–42.
Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, et al. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study. Liver Int. 2019;39(10):1852–9.
Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, et al. Effectiveness of 8-week glecaprevir/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther. 2020;37(5):2267–74.
Zamor P, Dillon J, Dylla D, Mutimer DJ, Ghalib R, Colombo M, et al. Outcomes of patients interrupting glecaprevir/pibrentasvir treatment: a case series from clinical trials. Hepatology. 2019;70:935A-A936.
Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112–21.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.
Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, et al. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016;16(1):1–10.
Nouch S, Gallagher L, Erickson M, Elbaharia R, Zhang W, Wang L, et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. Int J Drug Policy. 2018;59:76–84.
Gane EJ, De Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, et al., editors. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. In: The Liver Meeting Digital Experience™; 2020 Nov 13–16: virtual.
Emmanuel B, Wilson EM, O’Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2017;2(11):832–6.
AbbVie Inc. MappingHepC. Available at: https://mappinghepc.com/. Accessed on 3 Oct 2022.
Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, et al. Epidemiology and clinical characteristics of individuals with hepatitis C virus infection in the United States, 2017–2019. Adv Ther. 2021;38(12):5777–90.
Acknowledgements
Funding
AbbVie sponsored the study; contributed to its design; and participated in the collection, analysis, and interpretation of the data and in the writing, reviewing, and approval of the publication. AbbVie funded the Rapid Service and Open Access of this publication. All authors had access to relevant data, and participated in the writing, review, and approval of the publication. No honoraria or payments were made for authorship. Glecaprevir was identified by AbbVie and Enanta.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Medical Writing, Editorial, and Other Assistance
Medical writing services were provided by Natalie Mitchell, MSc, of Fishawack Facilitate, Ltd. (part of Fishawack Health, Conshohocken, PA), and funded by AbbVie. Statistical support services provided by Carlos Flores, MPH, of Genesis Research were funded by AbbVie.
Authorship Contributions
Wei-Han Cheng and Steven E. Marx led the study design, Qiujun Shao led statistical analyses, and Nancy Reau and Anthony Martinez provided guidance on study design. All authors reviewed and approved the final version of the article.
Disclosures
Nancy Reau has received consulting fees from AbbVie, Gilead Sciences, and Abbott. Her institution has received research support from Abbott and Gilead Sciences. Qiujun Shao is a previous employee of AbbVie who is currently employed by Novartis and does not own stocks and/or stock options of the company. Hannah Brooks is a previous employee of AbbVie who is currently employed by Pfizer Inc. and may own stocks and/or stock options of the company. Anthony Martinez has received consulting fees from Gilead Sciences, AbbVie, and Intercept. He has received research support from Allergan, Intercept, Gilead Sciences, and AbbVie. He reports being a speaker for AbbVie, Gilead Sciences, Eisai, Salix, and Sirtex. Wei-Han Cheng and Steven E. Marx are employees of AbbVie and may own stocks and/or stock options of the company.
Compliance with Ethics Guidelines
Data provided for the study were de-identified and Health Insurance Portability and Accountability Act (HIPAA) compliant, so review board approval was not required.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Qiujun Shao: Current employee of Novartis.
Hannah Brooks: Current employee of Pfizer Inc.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Reau, N., Cheng, WH., Shao, Q. et al. Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients. Infect Dis Ther 12, 1849–1860 (2023). https://doi.org/10.1007/s40121-023-00823-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40121-023-00823-z